JP2023521837A - 大きな配列の汎コロナウイルスワクチン組成物 - Google Patents

大きな配列の汎コロナウイルスワクチン組成物 Download PDF

Info

Publication number
JP2023521837A
JP2023521837A JP2022562334A JP2022562334A JP2023521837A JP 2023521837 A JP2023521837 A JP 2023521837A JP 2022562334 A JP2022562334 A JP 2022562334A JP 2022562334 A JP2022562334 A JP 2022562334A JP 2023521837 A JP2023521837 A JP 2023521837A
Authority
JP
Japan
Prior art keywords
composition
coronavirus
cell
protein
conserved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521837A5 (https=
Inventor
ベンモハメッド、ルバチール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2023521837A publication Critical patent/JP2023521837A/ja
Publication of JP2023521837A5 publication Critical patent/JP2023521837A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022562334A 2020-04-14 2021-04-14 大きな配列の汎コロナウイルスワクチン組成物 Pending JP2023521837A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063009907P 2020-04-14 2020-04-14
US63/009,907 2020-04-14
US202063084421P 2020-09-28 2020-09-28
US63/084,421 2020-09-28
PCT/US2021/027355 WO2021211760A1 (en) 2020-04-14 2021-04-14 Large sequence pan-coronavirus vaccine compositions

Publications (2)

Publication Number Publication Date
JP2023521837A true JP2023521837A (ja) 2023-05-25
JP2023521837A5 JP2023521837A5 (https=) 2024-04-22

Family

ID=78084328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562334A Pending JP2023521837A (ja) 2020-04-14 2021-04-14 大きな配列の汎コロナウイルスワクチン組成物

Country Status (9)

Country Link
US (1) US20230226173A1 (https=)
EP (3) EP4135764A4 (https=)
JP (1) JP2023521837A (https=)
KR (1) KR20230002571A (https=)
CN (1) CN116033920A (https=)
AU (1) AU2021254768A1 (https=)
CA (1) CA3178834A1 (https=)
IL (1) IL297335A (https=)
WO (3) WO2021211749A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12558415B2 (en) 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2022013609A1 (en) * 2020-07-13 2022-01-20 Immunovaccine Technologies, Inc. Sars-cov-2 vaccine compositions and methods of preparation and use
EP4333868A1 (en) * 2021-05-04 2024-03-13 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
MX2023013081A (es) * 2021-05-05 2024-01-15 Novavax Inc Composiciones de coronavirus e influenza y métodos para utilizarlas.
CN113185586B (zh) * 2021-05-18 2023-01-17 深圳市因诺转化医学研究院 SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用
AU2022308712A1 (en) * 2021-07-09 2023-12-21 Atossa Therapeutics, Inc. Compositions and methods to increase coronavirus immune response
WO2023283642A2 (en) * 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus concatemeric vaccines
WO2023044542A1 (en) * 2021-09-24 2023-03-30 The University Of Adelaide Sars cov-2 vaccine
CN114395017B (zh) * 2021-10-29 2024-08-13 中国科学院深圳先进技术研究院 SARS-CoV-2病毒样颗粒的制备方法及其应用
EP4176898A1 (en) * 2021-11-08 2023-05-10 Charité - Universitätsmedizin Berlin Pan sars-cov2 vaccine antigen
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN114181320B (zh) * 2021-12-09 2023-04-25 新疆医科大学第一附属医院 一种针对新冠原始株和变异株的重组多表位疫苗rSMEV及其应用
CN114478716B (zh) * 2021-12-28 2024-05-28 梅州市人民医院(梅州市医学科学院) 一种多肽组合及其在新型冠状病毒抗体检测中的应用
WO2023159082A2 (en) * 2022-02-15 2023-08-24 Ohio State Innovation Foundation Nanotechnology based intranasal vaccine for covid-19 comprising chitosan
WO2023240159A2 (en) * 2022-06-07 2023-12-14 The Regents Of The University Of California Sars-cov-2 multi-antigen universal vaccines
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024011163A1 (en) * 2022-07-06 2024-01-11 Georgia State University Research Foundation, Inc. Coronavirus vaccines and methods of use thereof
WO2024064965A2 (en) * 2022-09-23 2024-03-28 Advanced Rna Vaccine (Arv) Technologies, Inc. Nucleic acid-based universal vaccine and methods of use thereof
WO2024074634A1 (en) * 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
CN116041540B (zh) * 2022-11-18 2025-10-17 中山大学 一种增强新冠突变株疫苗广谱性的方法及新冠广谱疫苗
WO2024191944A2 (en) * 2023-03-10 2024-09-19 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
WO2024206843A2 (en) * 2023-03-31 2024-10-03 University Of Kansas Compositions including modified coronavirus vaccines and uses thereof
WO2024222737A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 工程化的mRNA及其用途
CN117903264B (zh) * 2023-10-26 2026-04-03 中国人民解放军海军军医大学 新冠病毒SARS-CoV-2 HLA-A2限制性表位肽及应用
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38A (en) 1836-10-04 Horizontal boot-clamp
US4079A (en) 1845-06-10 Corn-shei
FR1601438A (https=) 1968-10-17 1970-08-24
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
AU6526100A (en) 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
KR101255016B1 (ko) * 2004-04-09 2013-04-17 와이어쓰 엘엘씨 소포성 구내염 바이러스의 상승적 감쇠, 그의 벡터 및 그의 면역원성 조성물
ES2361000T3 (es) * 2004-04-28 2011-06-13 The Trustees Of The University Of Pennsylvania Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado.
EP1882187A4 (en) * 2005-05-12 2010-10-20 Merck Sharp & Dohme SYSTEM AND METHOD FOR THE AUTOMATED SELECTION OF T-CELL EPITOPES
AU2007281934B2 (en) * 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
ES2389121T3 (es) * 2007-02-27 2012-10-23 Wyeth Llc Composiciones inmunogénicas para el tratamiento y prevención de infecciones en animales
WO2009117134A2 (en) * 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
NZ602504A (en) * 2008-11-18 2014-01-31 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
MX2011010977A (es) * 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CN101792491B (zh) * 2009-11-05 2012-07-25 中国人民解放军第四军医大学 一种基于多串联表位的重组腺病毒hiv疫苗及其制备方法
CN111315407B (zh) * 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US12269846B2 (en) * 2020-03-05 2025-04-08 Swey-Shen Chen CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution
US20250108108A1 (en) * 2020-04-14 2025-04-03 The Regents Of The University Of California Hybrid flu-coronavirus vaccine
WO2022167571A1 (en) * 2021-02-04 2022-08-11 Imba - Institut Für Molekulare Biotechnologie Gmbh Treatment and method of identifying coronavirus therapeutics

Also Published As

Publication number Publication date
EP4135762A1 (en) 2023-02-22
EP4135762A4 (en) 2024-05-15
WO2021211749A1 (en) 2021-10-21
EP4135765A4 (en) 2024-05-08
AU2021254768A1 (en) 2022-11-17
WO2021211748A1 (en) 2021-10-21
US20230226173A1 (en) 2023-07-20
WO2021211760A1 (en) 2021-10-21
KR20230002571A (ko) 2023-01-05
CA3178834A1 (en) 2021-10-21
EP4135764A1 (en) 2023-02-22
IL297335A (en) 2022-12-01
EP4135764A4 (en) 2024-05-08
EP4135765A1 (en) 2023-02-22
CN116033920A (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
JP2023521837A (ja) 大きな配列の汎コロナウイルスワクチン組成物
US12171827B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
US20230173060A1 (en) Large sequence pan-coronavirus vaccine compositions
CA3167493A1 (en) T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19
TW202140794A (zh) 疫苗及其誘導對sars-cov2之免疫反應之用途
US20250108108A1 (en) Hybrid flu-coronavirus vaccine
Olech The genetic variability of small-ruminant lentiviruses and its impact on tropism, the development of diagnostic tests and vaccines and the effectiveness of control programmes
US12558415B2 (en) Broad-spectrum multi-antigen pan-coronavirus vaccine
EP2571519A1 (en) Marker vaccine for classical swine fever
CN117964720A (zh) HLA-A*02:01限制性SARS-CoV-2 T细胞表位肽及其应用
US20250360201A1 (en) Sars-cov-2 variants of concern-specific multi-antigens universal vaccine
EP4677097A2 (en) Broad-spectrum multi-antigen pan-coronavirus vaccine
WO2023240159A2 (en) Sars-cov-2 multi-antigen universal vaccines
RU2765658C9 (ru) Выделение нового пестивируса, вызывающего врожденный тремор а
RU2765658C2 (ru) Выделение нового пестивируса, вызывающего врожденный тремор а
KR101484305B1 (ko) Ｈ3 말 인플루엔자 ａ 바이러스
Rene'Johnson The role of secreted respiratory syncytial virus G glycoprotein in RSV pathogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316